Cargando…

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

BACKGROUND: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma e...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, David B., Bosnic-Anticevich, Sinthia, Pavord, Ian D., Roche, Nicolas, Halpin, David M. G., Bjermer, Leif, Usmani, Omar S., Brusselle, Guy, Ming, Simon Wan Yau, Rastogi, Sarang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702739/
https://www.ncbi.nlm.nih.gov/pubmed/31452870
http://dx.doi.org/10.1186/s13601-019-0282-7
_version_ 1783445286321913856
author Price, David B.
Bosnic-Anticevich, Sinthia
Pavord, Ian D.
Roche, Nicolas
Halpin, David M. G.
Bjermer, Leif
Usmani, Omar S.
Brusselle, Guy
Ming, Simon Wan Yau
Rastogi, Sarang
author_facet Price, David B.
Bosnic-Anticevich, Sinthia
Pavord, Ian D.
Roche, Nicolas
Halpin, David M. G.
Bjermer, Leif
Usmani, Omar S.
Brusselle, Guy
Ming, Simon Wan Yau
Rastogi, Sarang
author_sort Price, David B.
collection PubMed
description BACKGROUND: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. METHODS: This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 10(9) cells/L; non-high: < 0.300 × 10(9) cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. RESULTS: In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). CONCLUSION: The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13601-019-0282-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6702739
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67027392019-08-26 Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations Price, David B. Bosnic-Anticevich, Sinthia Pavord, Ian D. Roche, Nicolas Halpin, David M. G. Bjermer, Leif Usmani, Omar S. Brusselle, Guy Ming, Simon Wan Yau Rastogi, Sarang Clin Transl Allergy Research BACKGROUND: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. METHODS: This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 10(9) cells/L; non-high: < 0.300 × 10(9) cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. RESULTS: In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). CONCLUSION: The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13601-019-0282-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-21 /pmc/articles/PMC6702739/ /pubmed/31452870 http://dx.doi.org/10.1186/s13601-019-0282-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Price, David B.
Bosnic-Anticevich, Sinthia
Pavord, Ian D.
Roche, Nicolas
Halpin, David M. G.
Bjermer, Leif
Usmani, Omar S.
Brusselle, Guy
Ming, Simon Wan Yau
Rastogi, Sarang
Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
title Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
title_full Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
title_fullStr Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
title_full_unstemmed Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
title_short Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
title_sort association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702739/
https://www.ncbi.nlm.nih.gov/pubmed/31452870
http://dx.doi.org/10.1186/s13601-019-0282-7
work_keys_str_mv AT pricedavidb associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT bosnicanticevichsinthia associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT pavordiand associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT rochenicolas associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT halpindavidmg associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT bjermerleif associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT usmaniomars associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT brusselleguy associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT mingsimonwanyau associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
AT rastogisarang associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations